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Aim. To study the effect of EMAP II, IFN-2b and its medicinal preparations on the amount of O
6
-methylgua-
nine-DNA methyltransferase (MGMT) protein in human cells in vitro. Methods. The human cells of 4BL and
Hep-2 lines were treated with the purified recombinant proteins EMAP II, IFN-2b and its commercial me dicinal
preparations. Changes in the MGMT gene expression were studied at a protein level by Western blot analysis. Re-
sults. Treatment of Hep-2 and 4BL cells with EMAP II at the concentrations of 0.02 g/ml and 2 g/ml respecti-
vely led to induction of the MGMT gene expression. EMAP II at the concentrations of 0.2–20g/ml caused dec-
rease of the MGMT protein amount in Hep-2 cells. The regulating activity of EMAP II was also observed for MARP
(anti-Methyltransferase Antibody Recognizable Protein). IFN-2b and Laferon-PharmBiotek with the activity of
200 and 2000 IU/ml were shown to cause an increase of the MGMT protein amount in Hep-2 cells. Conclusions.
The purified recombinant proteins EMAP II and IFN-2b which are substrates for the medicinal preparations in-
fluenced on the amount of MGMT protein in the human cell cultures in a concentration-dependent manner. At the
same time the effect of medicinal preparations differs from that of the purified protein IFN-2b. Possibly it depends
on the presence of stabilizing components in their compositions.
Keywords: MGMT, MARP, IFN-2b, EMAP II, human cell cultures.
Introduction. The repair enzyme O6-methylguanine-
DNA methyltransferase (MGMT) eliminates O6-me-
thylguanin adducts in DNA and protects normal cells
from damaging effects of alkylating agents. At the sa-
me time MGMT makes tumor cells resistant to alkyla-
ting drugs such as temozolomide [1, 2].
Therefore, in medicine MGMT is considered as a
target which needs to be regulated. Various regulators
of theMGMT enzyme activity and expression are known
but they are often toxic not only for tumor but also for nor-
mal human cells [3]. Cytokines are natural factors and
some of themwere shown to be promising in theMGMT
gene expression regulation. For example, IFN- down-
regulated theMGMT transcription and sensitized the re-
sistant glioma and neuroblastoma cells to temozolomi-
de in vitro [4, 5]. One of the members of interleukin fa-
mily – IL-24 down-regulated the MGMT gene expres-
sion via activation of p53 and therefore helped to over-
come themelanoma cells resistance to temozolomide [6].
Interferons elicit pleiotropic biological effects, so
they are widely used either alone or in combination with
other antitumor agents, in particular with nitrosoureas.
Preadministration of interferons to patients might be a
part of a novel biochemotherapy approach that may help
to overcome the resistance to alkylating drugs. The com-
bined therapy with IFN- and temozolomide was shown
to provide better clinical outcomes in the patients who-
se tumor cells had an unmethylated MGMT promoter
[7]. For the patients with progressive malignant glioma,
the complex therapy with BCNU and IFN-2b (Intron
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A, «Schering Corporation», USA) appeared to be a fea-
sible and promising treatment strategy. The effect of
IFN-2b on the cell sensitivity to BCNUwas proposed
to be implemented by inhibition of the MGMT gene
expression [8]. However, this suggestion needs to be
confirmed.
EMAP II (endothelial monocyte-activating poly-
peptide II) is a multifunctional cytokine, which is for-
med inmalignant tumors of mammals due to the alterna-
tive splicing and posttranslational processing of its pre-
cursor – the p43 protein [9]. EMAP II suppresses the en-
dothelial cell migration; stimulates their apoptosis and
influences the activity of monocytes, neutrophils and
macrophages, facilitating inflammatory processes in
tumors [10]. The antitumor activity of this cytokine was
evidenced in the experimental models of glioma, sarco-
ma, stomach and pancreas cancer [11].
In our previous works different exogenous cytoki-
nes, growth factors and plant components (extracts, lec-
tins) were shown to be able to change the level of the
MGMT gene expression in some human cell cultures [12,
13]. To our opinion IFN-2b and EMAP II which pos-
sess antitumor activity were the most promising agents
for this purpose. One of the important questions in this
study was determination of the dependence of IFN-2b
and EMAP II action on their concentration. Moreover
the another problem has arrived: does the effect of cyto-
kine medicinal preparation differ from that of their pu-
rified substances?
Additionally it should be noted that the human
MGMT protein has a molecular weight of 22–24 kDa
[14]. However, in our previous works the Western blot
analysis with monoclonal anti-MGMT antibodies, clo-
ne 23.2, revealed two highly specific immunoreactive
bands: 24 kDa (classic MGMT protein) and 48 kDa (an-
ti-Methyltransferase Antibody Recognizable Protein or
MARP) [12, 15]. In those works the MARP nature and
its induction by exogenous cytokines in human cells in
vitro have been discussed.
The aim of the present work was to compare the ef-
fect of different concentrations of purified IFN-2b and
EMAP II and medicinal preparations of IFN-2b on the
MGMT and MARP protein amount in human cell
cultures.
Materials andmethods. The following human cell
lines were used: a standard line Hep-2 (laryngeal can-
cer) and 4BL line (fibroblast-like cells) derived in our la-
boratory [16]. Cells were cultivated in standard DMEM
(PAA) with 10 % FBS («Sigma») and antibiotics peni-
cillin (0.02 %) and streptomycin (0.02 %) at 37 oC with
4 % CO2.
The following interferon agents were used: human
recombinant protein IFN-2b («Interpharmbiotek»,
Ukraine) in 0.1 M NaCl; Laferon-PharmBiotek («In-
terpharmbiotek») containing the human recombinant
protein IFN- 2b and additional components: NaCl,
Dextran 70, KH2PO4, Na2HPO4; Laferobion («Biofar-
ma», Ukraine) containing the human recombinant pro-
tein IFN-2b and additional components: NaCl, Dext-
ran 70, KH2PO4, Na3PO4  12H2O.
Recombinant EMAP II proteinwas expressed inE. co-
li, purified and studied as described previously [17–20].
For cytokine treatments, 8 10
5 cells were plated and
allowed attaching during 24 h. The next day, the cells
were treated with cytokines and cytokine-containing
preparations in the serum-free DMEM growth medium.
After 8-h exposure the medium was removed, the cells
were rewashed with PBS buffer and harvested in DMEM
with 10 % of serum during 16 h. The cells were then
trypsinized, washed, centrifuged, and stored at –20 oC.
Control intact cells were subjected to the similar proce-
dure but without adding cytokines.
Protein extracts were obtained from cell pellets in
lysis buffer (50 mM Tris HCl; 0.1 mM EDTA; 5 mM
DTT; pH 7.5). The suspensions were incubated on ice,
exposed to three 10-s pulses of sonication with 30-s in-
tervals and 50 mM of PMSF in ethanol were added.
Sonicates were then centrifuged at 13,000 g for 30 min
at 4 oC. The supernatants were collected and frozen at
–80 oC for later use. SDS-PAGE (12 % gel) was perfor-
med by Laemmli method [21].
The concentration of total protein in cell lysates was
measured colorimetrically according to Bradford me-
thod [22].
The following antibodies were used: anti-MGMT
monoclonal antibodies, clone 23.2, isotype IgG2b («No-
vus Biologicals», USA), secondary antibodies conjuga-
ted with horseradish peroxidase («Sigma», USA). The
procedure of MGMT identification in the samples was
performed byWestern blot analysis according to theme-
thodological instructions of the manufacturer of mAbs
[23]. Densitometry of stained membranes was used for
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loading control according to [24] by ScionImage 4.0.2
and Origin 8.1 programs.
Results and discussion. It was shown by Western
blot analysis that cytokine EMAP II at a concentration
of 0.02g/ml induced theMGMT gene expression (Fig.
1, lane 2) in a clone of Hep-2 cells which did not ex-
press theMGMT gene under normal conditions (Fig. 1,
lane 1). However, an increase of EMAP II doses to 0.2–
20g/ml did not lead to any changes of theMGMT pro-
tein amount in these cells (Fig. 1, lanes 3–5). After the
treatment of Hep-2 cells, that normally expressed the
MGMT gene, with cytokine EMAP II at a concentration
of 2 g/ml we observed decrease of the MGMT protein
amount (Fig. 1, lanes 6 and 7). Thus, the EMAP II effect
on theMGMT protein amount in Hep-2 cells differs de-
pending on concentrations.
In our previous work, 4BL cells were shown to lose
the possibility to express the MGMT gene during more
than 130 passages cultivation and cell line stabilization
[26]. However, the treatment of these cells (137 passage)
with cytokine EMAP II led to induction of the MGMT
gene expression (Fig. 2), which allowed us to suggest re-
versibility of theMGMT gene silencing. Induction of the
MGMT gene expression in 4BL cells was detected after
8-h incubation with EMAP II at a concentration 2g/ml.
However this effect almost disappeared during longer
incubation time – 16 and 32 h (Fig. 2, lanes 3 and 4). A
reduction of the MGMT protein amount may be the re-
sult of increasing time of serum-free conditions.
The regulating activity of EMAP II was observed
not only for theMGMT protein but also for MARP. The
MARP protein is stably expressed in both Hep-2 and
4BL cells in contrast to MGMT. An inverse concentra-
tion dependence was observed after treatment of Hep-2
cells with recombinant protein EMAP II: at concentra-
tions of 0.02 and 0.2g/ml it induced theMARP expres-
sion, but at higher concentrations (2 and 20g/ml) it in-
hibited theMARP expression (Fig. 3, lanes 2–5). EMAP
II caused a slight increase of the MARP amount in 4BL
cells (Fig. 3, lanes 7–9).
In our earlier work IFN-2b-containing preparation
Laferobion («Biofarma») at concentrations of 200 and
2000 IU/ml was shown to cause a dramatic decrease in
the MGMT protein amount in Hep-2 cells [12]. How-
ever, in our current work it was shown that IFN-2b at
concentrations of 200 and 2000 IU/ml increases the
MGMT protein amount in Hep-2 cells (Fig. 4, lanes 2
and 3). The similar tendency was observed after treat-
ment of Hep-2 cells with Laferon-PharmBiotek prepa-
ration («Interpharmbiotech») (Fig. 4, lanes 6 and 7).
At the same time no changes in the MGMT protein
amount were observed after treatment of 4BL cells with
IFN-2b and Laferon (data not shown).
Laferon-PharmBiotek and Laferobion preparations
have similar composition (recombinant human IFN-2b,
salts, dext ran) but they showed an opposite effect on the
MGMT protein amount. According to the literature da-
ta, a preparation Intron A (recombinant IFN-2b, EDTA,
NaCl, m-Kresol, Polysorbate 80, Na2HPO4, NaH2PO4)
decreased the MGMT gene expression in patients, who
had progressive malignant glioma [8]. Thus Laferobion
and Intron A showed similar regu lating effects although
they have different composition of stabilizing compo-
nents [8, 12].
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Fig. 1. Effect of cytokine EMAP II at different concentrations on the
amount of MGMT protein in MGMT non-expressing (A) and MGMT-
expressing (B) Hep-2 cells: A – Western blot analysis (1 – 0 g/ml; 2 –
0.02 g/ml; 3 – 0.2 g/ml; 4 – 2 g/ml; 5 – 20 g/ml); B – Western
blot analysis (1 – 0g/ml; 2 – 2g/ml); C, D – results of densitometry
(the vertical bar represents the level of MGMT protein amount, conven-
tional densitometry units)
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Fig. 2. Time-dependent effect of cytokine EMAP II on the amount of
MGMT protein in 4BL cells: A – Western blot analysis; 1–4 – 4BL,
137 passages + EMAP II (1 – 0g/ml, 8 h; 2 – 2g/ml, 8 h; 3 – 2g/ml,
16 h; 4 – 2g/ml, 32 h); B – results of densitometry (the vertical bar re-
presents the level of MGMT protein amount, conventional densitomet-
ry units)
According to these data we may suggest that regula-
ting effect of the IFN-2b-containing preparations de-
pends not only on the composition but also on their puri-
fication degree. Therefore these results could be useful
for planning the experiments with the IFN-2b-contai-
ning preparations and for IFN-2b therapy.
There are several hypotheses about the mechanisms
of theMGMT gene expression regulation under the in-
fluence of cytokines. According to one of them IFN-
regulates the MGMT transcription via p53 protein and
specificity protein 1 (Sp1) [4, 5]. Another one suggests
that IFN- activates transcriptional factor NF-B and
thus affects the transcription ofMGMT gene, which be-
longs to the NF-B target genes [26]. According to the
literature data, all IFNs of type I (IFN-, IFN-, IFN-	,
IFN-
) bind to the specific cell surface receptor comp-
lex known as the IFN- receptor (IFNAR) [27]. There-
fore we suppose that regulation of theMGMT gene ex-
pression by IFN- and IFN-2b may involve the similar
pathways (Fig. 5).
The way of EMAP II impact on theMGMT gene ex-
pression remains unclear. In some works it was shown
that EMAP II at low and high concentrations activates
various signaling pathways in cells [28, 29]. For ins-
tance, in a blood–tumor barrier (BTB) model, EMAP II
at low concentration (0.05 nM) induced three isoforms
of protein kinase C (PKC): PKC-,, and, and, through
them, caused functional, biochemical, and morpholo-
gical alterations in BTB [29]. PKC is known to regulate
theMGMT gene expression [30]. Its regulating effect is
mediated by binding to an activator protein 1 (AP-1)
and further binding to the AP-1 site in the MGMT gene
promotor, affecting theMGMT gene transcription. Mo-
reover, EMAP II can also activate the NF-B trans-
cription factor [31]. Therefore we suppose that regula-
tion of the MGMT gene expression by IFN-2b and
EMAP II occurs with participation of transcription fac-
tors NF-B, Sp1 and AP-1. A scheme of possible cell sig-
naling pathways involved in these processes is shown
in Fig. 5.
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Fig. 3. Effect of recombinant protein EMAP II on the amount of MARP
in human cell cultures: A – 1–5 – Hep-2 + EMAP II (1 – 0 g/ml; 2 –
0.02g/ml; 3 – 0.2g/ ml; 4 – 2g/ml; 5 – 20 g/ml); 6–9 – 4BL, 137
p. + EMAP II (6 – 0g/ml, 8 h; 7 – 2g/ml, 8 h; 8 – 2g/ml, 16 h; 9 – 2
g/ml, 32 h); B – results of densitometry (the vertical bar represents the
level of MARP amount, conventional densitometry units)
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Fig. 4. Effect of IFN-2b and Laferon-PharmBiotek on the MGMT
protein amount in Hep-2 cells: A –Western blot analysis (1 – IFN-2b,
0 IU/ml; 2 – IFN-2b, 2000 IU/ml; 3 – IFN-2b, 200 IU/ml; 4 –
IFN-2b, 2 IU/ml; 5 – Laferon, 0 IU/ml; 6 – Laferon, 2000 IU/ml; 7 –
Laferon-PharmBiotek, 200 IU /ml); B – results of densitometry (the ver-
tical bar represents the level of MGMT protein amount, conventional
densitometry units)
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Fig. 5. Possible cell signaling pathways involved in regulation of the
MGMT gene expression under the influence of IFN-2b and EMAP II;
STAT3 – Signal transducer and activator of transcription 3; ISGF3 –
Interferon-stimulated gene factor 3
We plan further study of the mechanisms of the
MGMT gene expression regulation under the influence
of cytokines to establish a connection between the action
of cytokines and the repair processes in human cells.
Conclusions. The EMAP II influence on the MGMT
protein amount depends on the concentration. The treat-
ments with cytokine IFN-2b at concentrations of 200
and 2000 IU/ml lead to the increase of MGMT protein
amount in Hep-2 cells. The effect of the purified protein
IFN-2b on the MGMT and MARP protein amounts
differs from that of medicinal preparations. Possibly it
depends on the presence of stabilizing components in
their compositions.
Âïëèâ EMAP II, IFN-2b òà éîãî ìåäè÷íèõ ïðåïàðàò³â
íà ê³ëüê³ñòü á³ëêà MGMT ó êë³òèíàõ ëþäèíè in vitro
Ê. Â. Êîöàðåíêî, Â. Â. Ëèëî, Ò. Ï. Ðóáàí, Ë. Ë. Ìàöåâè÷,
Î. ². Êîðíåëþê, Ñ. ². ×åðíèõ, Ë. Ë. Ëóêàø
Ðåçþìå
Ìåòà. Äîñë³äèòè âïëèâ EMAP II, IFN-2b òà éîãî ìåäè÷íèõ ïðå-
ïàðàò³â íà ê³ëüê³ñòü á³ëêà MGMT ó êë³òèíàõ ëþäèíè in vitro.Ìå-
òîäè. Êë³òèíè ëþäèíè 4BL ³ Hep-2 îáðîáëÿëè EMAP II, IFN-2b ³
éîãî êîìåðö³éíèìè ïðåïàðàòàìè. Çì³íè â åêñïðåñ³¿ ãåíà MGMT íà
ð³âí³ á³ëêà äîñë³äæóâàëè çà âèêîðèñòàííÿ Âåñòåðí-áëîò àíàë³çó.
Ðåçóëüòàòè. Îáðîáêà êë³òèí Hep-2 ³ 4BL öèòîê³íîì EMAP II â
êîíöåíòðàö³¿ 0,02 ³ 2 ìêã/ìë â³äïîâ³äíî ïðèçâîäèòü äî ³íäóêö³¿ åêñ-
ïðåñ³¿ ãåíà MGMT. EMAP II â êîíöåíòðàö³ÿõ 0,2–20 ìêã/ìë çíè-
æóº ê³ëüê³ñòü á³ëêà MGMT ó êë³òèíàõ Hep-2. Ðåãóëþâàëüíó àê-
òèâí³ñòü EMAP II ñïîñòåð³ãàëè òàêîæ ³ â³äíîñíî MARP (á³ëêà,
ÿêèé ðîçï³çíàºòüñÿ ìîíîêëîíàëüíèìè àíòè-MGMT àíòèò³ëàìè).
Ïîêàçàíî, ùî IFN-2b ³ Ëàôåðîí-ÔàðìÁ³îòåê ç àêòèâí³ñòþ 200 ³
2000 ÌÎ/ìë ï³äâèùóþòü ê³ëüê³ñòü á³ëêà MGMT ó êë³òèíàõ Hep-2.
Âèñíîâêè. Î÷èùåí³ ðåêîìá³íàíòí³ á³ëêè EMAP II ³ IFN-2b, ÿê³ º
ñóáñòðàòàìè äëÿ ìåäè÷íèõ ïðåïàðàò³â, âïëèâàþòü íà ê³ëüê³ñòü
á³ëêà MGMT ó êë³òèíàõ ëþäèíè in vitro çàëåæíî â³ä êîíöåíòðàö³¿.
Ó òîé æå ÷àñ ä³ÿ ìåäè÷íèõ ïðåïàðàò³â â³äð³çíÿºòüñÿ â³ä åôåêòó
î÷èùåíîãî á³ëêà IFN-2b, ùî, ìîæëèâî, ïîâ’ÿçàíî ç ïðèñóòí³ñòþ
ñòàá³ë³çóâàëüíèõ êîìïîíåíò³â ó éîãî ñêëàä³.
Êëþ÷îâ³ ñëîâà: MGMT, MARP, IFN-2b, EMAP II, êóëüòóðè êë³-
òèí ëþäèíè.
Âëèÿíèå EMAP II, IFN-2b è åãî ìåäèöèíñêèõ ïðåïàðàòîâ
íà êîëè÷åñòâî áåëêà MGMT â êëåòêàõ ÷åëîâåêà in vitro
Å. Â. Êîöàðåíêî, Â. Â. Ëûëî, Ò. À. Ðóáàí, Ë. Ë. Ìàöåâè÷,
À. È. Êîðíåëþê, Ñ. È. ×åðíûõ, Ë. Ë. Ëóêàø
Ðåçþìå
Öåëü. Èññëåäîâàòü âëèÿíèå EMAP II, IFN-2b è åãî ìåäèöèíñêèõ
ïðåïàðàòîâ íà êîëè÷åñòâî áåëêà MGMT â êëåòêàõ ÷åëîâåêà in vit-
ro. Ìåòîäû. Êëåòêè ÷åëîâåêà 4BL è Hep-2 îáðàáàòûâàëè EMAP
II, IFN-2b è åãî êîììåð÷åñêèìè ïðåïàðàòàìè. Èçìåíåíèÿ â ýêñ-
ïðåññèè ãåíà MGMT èññëåäîâàëè ñ èñïîëüçîâàíèåì Âåñòåðí-áëîò
àíàëèçà. Ðåçóëüòàòû. Îáðàáîòêà êëåòîê Hep-2 è 4BL öèòîêèíîì
EMAP II â êîíöåíòðàöèè 0,02 è 2 ìêã/ìë ñîîòâåòñòâåííî ïðèâîäèò
ê èíäóêöèè ýêñïðåññèè ãåíà MGMT. EMAP II â êîíöåíòðàöèÿõ 0,2–
20 ìêã/ìë ñíèæàåò óðîâåíü ýêñïðåññèè ãåíà MGMT â êëåòêàõ
Hep-2. Ðåãóëèðóþùóþ àêòèâíîñòü EMAP II íàáëþäàëè òàêæå è
îòíîñèòåëüíî MARP (áåëêà, ðàñïîçíàâàåìîãî ìîíîêëîíàëüíûìè
àíòè-MGMT àíòèòåëàìè). Ïîêàçàíî, ÷òî IFN-2b è Ëàôåðîí-
ÔàðìÁèîòåê ñ àêòèâíîñòüþ 200 è 2000 ÌÅ/ìë ïîâûøàþò êîëè-
÷åñòâî áåëêà MGMT â êëåòêàõ Hep-2. Âûâîäû. Î÷èùåííûå ðåêîì-
áèíàíòíûå áåëêè EMAP II è IFN-2b, ÿâëÿþùèåñÿ ñóáñòðàòàìè
äëÿ ìåäèöèíñêèõ ïðåïàðàòîâ, âëèÿþò íà êîëè÷åñòâî áåëêà MGMT
â êëåòêàõ ÷åëîâåêà in vitro çàâèñèìûì îò êîíöåíòðàöèè îáðàçîì.
Â òî æå âðåìÿ äåéñòâèå ìåäèöèíñêèõ ïðåïàðàòîâ îòëè÷àåòñÿ
îò âëèÿíèÿ î÷èùåííîãî áåëêà IFN-2b, ÷òî, âîçìîæíî, ñâÿçàíî ñ
ïðèñóòñòâèåì ñòàáèëèçèðóþùèõ êîìïîíåíòîâ â åãî ñîñòàâå.
Êëþ÷åâûå ñëîâà: MGMT, MARP, IFN-2b, EMAP II, êóëüòóðû
êëåòîê ÷åëîâåêà.
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